Alx Oncology Holdings (ALXO) FCF Margin (2019 - 2020)
Alx Oncology Holdings (ALXO) posted FCF Margin of 1169.45% for Q2 2020, up 14.63% sequentially from 1369.92% in Q1 2020.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) FCF Margin (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported FCF Margin for 2 years, with the latest figure at 1169.45% in Q2 2020.
- Quarterly FCF Margin changed N/A year-over-year to 1169.45% in Q2 2020, while the trailing twelve-month figure through Mar 2021 was 6544.4% (down 620562.0% YoY) and the FY2020 annual result came in at 3241.96%, down 293750.0% from the prior year.
- FCF Margin grew to 1169.45% in Q2 2020 per ALXO's latest filing, from 1369.92% in the prior quarter.
- Over five years, FCF Margin peaked at 231.82% in Q4 2019 and troughed at 1369.92% in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Alx Oncology Holdings | 272.64 Mn | 272.64 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | -1,538.14% |
| Mar 31, 2020 | -1,369.92% |
| Dec 31, 2019 | -231.82% |
| Sep 30, 2019 | -253.66% |